Videos

Yi-Bin Chen, MD, gives insight into the current accuracy of predictive prognostics and the potential use of biomarkers to risk stratify patients with acute GvHD in the future.

Yi-Bin Chen, MD, provides an overview of the case of a 50-year-old woman with steroid-refractory acute GvHD, including initial presentation, clinical work-up, and treatment.

Yi-Bin Chen, MD, reviews the case of a 50-year-old woman with steroid-refractory acute graft versus host disease (aGvHD) following allogeneic transplant and provides a discussion on treatment considerations for patients with aGvHD.

Othman Al-Sawaf, MD, discusses an analysis of minimal residual disease in patients with chronic lymphocytic leukemia given venetoclax and obinutuzumab on the CLL14.

Richard Finn, MD, discusses the interim results of the REFINE Study, which tests the real-world dosing of regorafenib in patients with unrespectable hepatocellular carcinoma.

Debu Tripathy, MD, discusses escalation and de-escalation of treatment in patients with HER2-positive breast cancer with HER2-targeted agents and chemotherapy.

Curtis Lachowiez, MD, discusses the interim analysis of the phase 1b/2 study of venetoclax in combination with standard intensive acute myeloid leukemia induction plus consolidation therapy with the FLAG-IDA regimen as treatment of patients with newly diagnosed or relapsed/refractory AML

Adam M. Brufsky, MD, PhD, discusses the use of neoadjuvant therapy for patients with triple–negative breast cancer.

Robert Coleman, MD, FACOG, FACS, discusses the research model he utilizes to bring more patient research to the lung cancer field, a topic he presented on during the Association of Community Cancer Centers Annual Meeting.

Markus Moehler, MD, PhD, discusses the survival outcomes of nivolumab in combination with chemotherapy in patients with advanced gastric cancer.

Brian I. Rini, MD, discusses the dosing of nivolumab plus ipilimumab for patients with renal cell carcinoma.

Hossein Borghaei, DO, MS, discusses some adverse events (AEs) associated with the use of immunotherapy for lung cancer.

Sergio Giralt, MD, discusses the current unmet medical needs for patients with relapsed/refractory acute myeloid leukemia.

Yi Lin, MD, PhD, explains the potential impact the approval of idecabtagene vicleucel could bring to the multiple myeloma field.

Lucia Masarova, MD, discusses the efficacy of CPI-0610 in the phase 2 MANIFEST trial in patients with myelofibrosis.

Shana Wingo, MD, talks about the challenges of treating patients in the Greater Phoenix, Arizona area.

Kami Maddocks, MD, discusses potential treatments in follicular lymphoma.

Ruth He, MD, grants advice on how to treat patients with unresectable hepatocellular carcinoma.

Ruth He, MD, discusses potential options for physicians in their treatment of unresectable hepatocellular carcinoma.

Ruth He, MD, acknowledges the current struggles experts face in combatting unresectable hepatocellular carcinoma.

Ruth He, MD, discusses the approval of frontline atezolizumab-bevacizumab and its relation to subsequent treatment of patients with unresectable hepatocellular carcinoma.

Ruth He, MD, discusses major takeaways from the phase 3 IMbrave150 trial of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.

Ruth He, MD, highlights factors that influence her use of frontline systemic therapy in patients with unresectable hepatocellular carcinoma.

Ruth He, MD, discusses the current treatment options for unresectable hepatocellular carcinoma.

Anthony Mato, MD, MSCE, discusses an observational registry study of real-world prognostic biomarker testing, treatment patterns and treatment dosing in a pool of 1461 patients with either chronic lymphocytic leukemia.

Ping Chi, MD, a medical oncologist, and Geoffrey Beene Junior Faculty chair at Memorial Sloan Kettering Cancer Center, reviews the results of a phase 2 study of binimetinib plus imatinib as treatment of patients with untreated advanced gastrointestinal stromal tumors.

William G. Wierda, MD, PhD, discusses challenges faced in when investigating ibrutinib and venetoclax in the CAPTIVATE trial for patients with chronic lymphocytic leukemia.

The final patient with glioblastoma multiforme has been enrolled in the ongoing phase 2 clinical trial of VAL-083, which is evaluating the efficacy, safety, and pharmacokinetics of the agent in patients who have been pre-treated with temozolomide prior to disease recurrence.

Constantine Tam, MD, discuses the outcomes of the phase 3 Sympatico Study, which evaluated the safety and efficacy of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for the treatment of relapsed or refractory mantle cell lymphoma compared to monotherapy.

Andrew Spencer, MD, MBBS, discusses the PANORAMA 3 trial data of oral panobinostat plus subcutaneous bortezomib and dexamethasone versus placebo, bortezomib, and dexamethasone.